Dr. John Cush RheumNow
1 year 8 months ago
Dr. Alexi Grom (video) discusses his presentation from ACR 2024, on the 80% success rate of an anti-IFN gamma mAb (emapalumab) when used in 39 Stills disease patients complicated by life-threatening macrophage activation syndrome. https://t.co/kIPmsVXkCP https://t.co/ib9pKEpZ4L
Dr. John Cush RheumNow
1 year 8 months ago
EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx https://t.co/Wm2ciKbMtY
Despite all its benefits, ultrasound’s daily clinical use remains the domain of only a subset of interested rheumatologists. If the benefits are so clear, then why is it not universal? In the late-breaking oral abstracts at ACR Convergence, the final abstract presentation was from the Danish rheumatologists behind ARTHUR and DIANA: the robot which holds the MSK ultrasound probe, and the artificial intelligence brains which empowers it. Perhaps
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
Dr. John Cush RheumNow
1 year 8 months ago
Novel TYK2 inhibitor Zasocitinib
Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/eDcx4AAnAs https://t.co/Y8Rso7h5t2
Dr. John Cush RheumNow
1 year 8 months ago
ACR24 RA Topic Panel: Innovations in Rheumatoid Arthritis https://t.co/dHiRacDmWc
Dr. John Cush RheumNow
1 year 8 months ago
ACR24 PsA Topic Panel Advancing Care for Psoriatic Arthritis
Tune in for an engaging discussion at the ACR Annual Meeting! This expert panel will explore the latest breakthroughs and trends in Psoriatic Arthritis(PsA) research and management, providing actionable insights for… https://t.co/j0063RpVCi https://t.co/LCINZvUR5s
Dr. John Cush RheumNow
1 year 8 months ago
Standardizing Still’s Disease Research: Global Data Harmonization Needed
A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).… https://t.co/ugsfRj2fnS https://t.co/UJmNvAMo1c
Dr. John Cush RheumNow
1 year 8 months ago
ACR24 SpA Panel: Key Discussions on Spondyloarthritis
Join panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Lihi Eder and Dr. Marina Magrey as they discuss key highlights and takeaways on spondyloarthritis sessions and abstracts presented at the 2024 ACR meeting in Washington,… https://t.co/XGcR6WDBFO https://t.co/0mJ08nheJJ
Dr. John Cush RheumNow
1 year 8 months ago
Study of 16,598 CAD pts showed in pts w/ normal hsCRP<2mg/L, increasing SUA didnt predict CV/MACE events. But if the hsCRP≥2 mg/L, increasing urate(SUA)was signif. assoc w/ increased MACE. Each 1mg incr in SUA yielded an 11% increase in MACE (adj p < 0.001)… https://t.co/9ehtOcoeBK https://t.co/t9IWQ8WUvY
Dr. John Cush RheumNow
1 year 8 months ago
Autoantibodies, found in over half of adult and paediatric patients with idiopathic inflammatory myopathies (IIMs), these correlate with clinical phenotypes, aiding in classification and prognosis. https://t.co/ZRXqtEec6s https://t.co/jkUe9bRlmU
Dr. John Cush RheumNow
1 year 8 months ago
Why should rheumatologists care about aging?
As a herald to what was to come in Washington, the publication of the Lancet Rheumatology series on aging coming just days before #ACR24 set the stage for the “grey tsunami” of geriatric rheumatology that was to follow.… https://t.co/XfB7ykV0Xs https://t.co/51Cjz3EGyn
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases.
